Guangdong WeSail Biotech Co., Ltd. (WeSail), with its strong business philosophy of “strive for excellence, truth and reality”, attaches great importance to technology innovation, product technological experiments, and the research of product advancement. The company is committed to supporting IVD diagnostic partners with excellent performance reagents and analyzers, including colloid gold and immunofluorescence platforms.
Based on deep insights into the future industry development trends, WeSail continuously launches reagents and analyzers meeting customer needs in various disease areas, including cardiovascular, metabolism, fertility, inflammation, diabetes, hormone, brain injury, renal injury, thyroid, tumor marker, etc. By bringing in more convenient, rapid and accurate tests to patients, WeSail fulfills the essence of POCT products to the world and continues to maintain a leading technology level among players in the global POCT industry.
At the end of 2019, a new strain of coronavirus was found and quickly accelerated into a global outbreak (named as COVID-19). WeSail, as a reagent R&D and production organization, shoulders the social responsibility of epidemic prevention and urgently develops testing reagents. At the beginning of 2020, a colloidal gold test kit for detecting COVID-19 was launched, which greatly shortened the diagnosis time. WeSail products are applicable in a wide range of scenarios. By defining the product layouts as subdivided fields and promoting industrial technological innovation, we will set sail with customers and the future!